Biogen Initiates Global Phase 3 PROMINENT Study for Felzartamab in ...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with…

Biogen Initiates Global Phase 3 PROMINENT Study for Felzartamab in ...

Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

Biogen begins Phase III trial for primary membranous nephropathy

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.The post Biogen begins Phase III trial for primary membranous nephropathy appeared first on Clinical Trials Arena.

Biogen and Genentech Urged to Limit Discussion of Damages in Upcoming Trial - USA Herald

In the breach-of-contract case between Biogen Inc. and Genentech Inc., a California federal judge advised both parties on Friday to refrain from emphasizing the “magnitude of the money at issue” during the upcoming trial regarding unpaid patent royalties related to Biogen’s multiple sclerosis treatment, Tysabri. U.S. District Judge Yvonne Gonzalez Rogers, presiding over the Northern